1800 244 735

Helpline (02) 9874 9777

Huntington’s Disease research update

Handwriting Can Help Identify Asymptomatic Huntington’s, Study Suggests.

WORDS Alberto Molano, PhD from Huntington’s Disease News

ANALYSIS OF handwriting movements using a pen tablet and specialised software can accurately distinguish  people with Huntington’s disease who are still asymptomatic from those without the disease, a new study suggests.

The findings also reveal that certain stroke  features  differ significantly between healthy individuals and patients who are already experiencing Huntington’s symptoms.

The research, “Handwriting Movement abnormalities in Symptomatic and premanifest huntington’s Disease,” was published in the journal Movement Disorders Clinical Practice.

Handwriting abnormalities in huntington’s patients were last reported nearly 20 years ago, and included longer stroke duration and greater variability in stroke velocity. among questions still unanswered is whether assessing handwriting movements can help detect abnormalities in the asymptomatic (premanifest) stage of Huntington’s and serve as a predictor of disease progression.

To investigate, researchers at university of California San Diego test- ed whether handwriting abnormalities were associated with clinical features in symptomatic patients, and if such abnormalities could distinguish asymptomatic Huntington’s patients from healthy controls.

The team asked participants to complete five simple tasks: draw simple loops left to right (a string of “l” letters in cursive writing), complex loops (“lleel- lee”), rapid overlay circles, and spirals, and write the  sentence “today is a nice day.”

Participants used a Wacom digitizing  tablet,  a  device  often used by artists to draw on a computer  screen.  the  tablet  has  a special pen and is sensitive to the level of applied pressure, mimicking traditional drawing on paper. Handwriting traces were recorded and analyzed using a specialized software called MovAlyzeR.

The study involved 38 symptomatic patients (mean age of 55 years), 30 asymptomatic individuals at risk for symptomatic disease (45 years), and 25 healthy controls (44 years).

Results revealed significantly longer and more variable stroke du- ration, as well as decreased hand- writing smoothness, and increased and more variable pen pressures in the handwriting of Huntington’s patients compared with the handwriting of the healthy controls.

Longer stroke duration was associated with greater penney burden of pathology (BOP) and CAG × age product, two measures of disease progression. Of note, the CAG × age product is calculated by multiplying the number of CAG repeats by the patient’s age.

CAG repeats are the genetic abnormality in people with huntington’s. Patients may have 36 to more than 120 of these repeats of three DNA building blocks (cytosine, adenine, and guanine) in their HTT gene. The longer this region is, the earlier the symptoms appear and the more severe the disease.

Handwriting abnormalities in Huntington’s patients were last reported nearly 20 years ago...

Data also showed that analysis of certain handwriting features could distinguish asymptomatic patients from controls with 85% accuracy, 90% sensitivity, and 80% specificity. these included greater variability in stroke amplitude, velocity and pen pressure, higher levels of pen pressure, longer stroke durations, and lower velocities for combinations of handwritten circles, sentences, and spirals.

“These findings support the clinical utility of dynamic measures of hand- writing kinematics as a potential early behavioral biomarker in [huntington’s],” the researchers wrote.

However, they cautioned that these results require confirmation, especially those in asymptomatic patients, and that studies in larger groups are still needed.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Published date: 22 October, 2020

While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation to branaplam. An existing drug…for huntingtin lowering? The pharmaceutical company Novartis has announced that the U.S. Food and Drug Administration ... Read more Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Updates from the EHDN Plenary Meeting 2020

Published date: 9 October, 2020

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more Updates from the EHDN Plenary Meeting 2020

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

When genes are unstable: targeting somatic instability in HD

Published date: 8 September, 2020

What is somatic instability? We tend to think of DNA as a fixed blueprint, an overarching plan for the biological bricks and bridges that constitute our cells, organs, and bodies. But like any good plan, DNA is actually dynamic and adaptable. It gets frequent use as a template for creating the RNA messages that pave ... Read more When genes are unstable: targeting somatic instability in HD

Working as a team: Changes in brain development mean some brain regions may be slacking off

Published date: 17 August, 2020

The effect of the HD genetic expansion on brain development has been a hot topic in HD research. A team of researchers led by Dr. Sandrine Humbert at the Grenoble Institut Neurosciences, examined human fetal tissue to show that the mutant HD gene causes very early changes in the patterns of early brain development. But ... Read more Working as a team: Changes in brain development mean some brain regions may be slacking off

Caution urged for the use of gene-editing technology CRISPR

Published date: 12 August, 2020

A gene-editing tool known as CRISPR has been heralded as a breakthrough technology for scientists in the lab but also as a potential strategy to treat numerous genetic diseases, including Huntington’s. But a series of recent studies has suggested that CRISPR is less precise than previously thought, leading to unintended changes in the genome. Three ... Read more Caution urged for the use of gene-editing technology CRISPR

Welcome to our new website!

Please bear with us while we iron out the last minute wrinkles! If you have any feedback about our new site, please fill out the form below.